Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs
March 29, 2023 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2022, and provides updates on its antiviral...
Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023
March 22, 2023 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and co-CEO, will present a company overview at the Virtual Investor Summit...
Cocrystal Pharma Announces Participation in Virtual Investor Events
January 26, 2023 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the participation of James Martin, co-CEO and CFO, in the following virtual investment community...
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
December 19, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor...
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
December 01, 2022 16:05 ET
|
Cocrystal Pharma, Inc.
Affirms plans to report topline Phase 1 results in 2022 and to initiate Phase 2a influenza human challenge trial in 2023 BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc....
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
November 17, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced that CC-42344 demonstrated a favorable safety profile in both the single-ascending dose and...
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
November 14, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
Completed enrollment in the Phase 1 study with novel, broad-spectrum antiviral PB2 candidate CC-42344 for the treatment of pandemic and seasonal influenza A; remains on track to report topline results...
Cocrystal Pharma to Participate in Two Investor Conferences in November
November 02, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investor conferences as follows: 2022 BioFlorida...
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza
November 01, 2022 16:05 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces it has been granted European patent EP3866778 titled "Combinations Of Inhibitors of Influenza Virus...
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
October 26, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the completion of enrollment in a Phase 1 healthy volunteer study to assess the safety, tolerability...